ovarian cancer

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

News

Dr Dominik Schumacher, Tubulis' co-founder and chief executive

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

Corcept gets FDA OK for first-in-class ovarian cancer drug

New hope for ovarian cancer, with Alexander Schneider

Ovarian cancer data restores faith in Corcept's relacorilant

Germany's Tubulis raises €308m for ADC pipeline

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

Ignota vacuums up Kronos Bio's drug programmes

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

ovarian cancer

Editor's Picks